318 related articles for article (PubMed ID: 16135341)
1. A research agenda for economic evaluation of substance abuse services.
French MT; Drummond M
J Subst Abuse Treat; 2005 Sep; 29(2):125-37. PubMed ID: 16135341
[TBL] [Abstract][Full Text] [Related]
2. Organizational and client determinants of cost in outpatient substance abuse treatment.
Beaston-Blaakman A; Shepard D; Horgan C; Ritter G
J Ment Health Policy Econ; 2007 Mar; 10(1):3-13. PubMed ID: 17417043
[TBL] [Abstract][Full Text] [Related]
3. Guidelines and challenges for estimating the economic costs and benefits of adolescent substance abuse treatments.
Zavala SK; French MT; Henderson CE; Alberga L; Rowe C; Liddle HA
J Subst Abuse Treat; 2005 Oct; 29(3):191-205. PubMed ID: 16183468
[TBL] [Abstract][Full Text] [Related]
4. Economic costs of drug abuse: financial, cost of illness, and services.
Cartwright WS
J Subst Abuse Treat; 2008 Mar; 34(2):224-33. PubMed ID: 17596904
[TBL] [Abstract][Full Text] [Related]
5. A critical review of accounting and economic methods for estimating the costs of addiction treatment.
Cartwright WS
J Subst Abuse Treat; 2008 Apr; 34(3):302-10. PubMed ID: 17614244
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of integrated care for people with HIV, chronic mental illness and substance abuse disorders.
Weaver MR; Conover CJ; Proescholdbell RJ; Arno PS; Ang A; Uldall KK; Ettner SL
J Ment Health Policy Econ; 2009 Mar; 12(1):33-46. PubMed ID: 19346565
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of a mixed-gender aftercare program for substance abuse: decomposing measured and unmeasured gender differences.
Yeom HS; Shepard DS
J Ment Health Policy Econ; 2007 Dec; 10(4):207-19. PubMed ID: 18166831
[TBL] [Abstract][Full Text] [Related]
8. Multidimensional impact of treatment for substance abuse.
Hoffmann NG; Harrison PA; Belille CA
Adv Alcohol Subst Abuse; 1984; 3(3):83-94. PubMed ID: 6496235
[TBL] [Abstract][Full Text] [Related]
9. A profile of the substance abuse treatment industry: organization, costs, and treatment completion.
Woodward AM; Raskin IE; Blacklow B
Subst Use Misuse; 2008; 43(5):647-79. PubMed ID: 18393082
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and benefit-cost of peer-based workplace substance abuse prevention coupled with random testing.
Miller TR; Zaloshnja E; Spicer RS
Accid Anal Prev; 2007 May; 39(3):565-73. PubMed ID: 17125723
[TBL] [Abstract][Full Text] [Related]
11. Forecasting the cost of drug abuse treatment coverage in private health insurance.
McGuire TG; Shatkin BF
NIDA Res Monogr; 1991; 113():175-89. PubMed ID: 1762639
[No Abstract] [Full Text] [Related]
12. [Recent developments in the economic evaluation of health].
Rovira J
Med Clin (Barc); 2000; 114 Suppl 3():8-14. PubMed ID: 10994558
[TBL] [Abstract][Full Text] [Related]
13. [Health services and health economics].
Cilingiroglu N
Nufusbil Derg; 1988; 10():45-50. PubMed ID: 12342133
[TBL] [Abstract][Full Text] [Related]
14. Economic evaluation of telemedicine: review of the literature and research guidelines for benefit-cost analysis.
Dávalos ME; French MT; Burdick AE; Simmons SC
Telemed J E Health; 2009 Dec; 15(10):933-48. PubMed ID: 19954346
[TBL] [Abstract][Full Text] [Related]
15. Does treatment 'pay for itself'? Looking at the economic argument for addiction treatment.
Ettner SL
Behav Healthc; 2006 May; 26(5):32-4. PubMed ID: 16736917
[No Abstract] [Full Text] [Related]
16. The role of health economics in substance abuse research. Recent advances and future opportunities. Overview.
French MT
Recent Dev Alcohol; 2001; 15():201-8. PubMed ID: 11449742
[No Abstract] [Full Text] [Related]
17. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
18. Intensive case management for youth with serious emotional disturbance and chemical abuse.
Evans ME; Dollard N
NIDA Res Monogr; 1992; 127():289-315. PubMed ID: 1436000
[No Abstract] [Full Text] [Related]
19. Cost estimation when time and resources are limited: the Brief DATCAP.
French MT; Roebuck MC; McLellan AT
J Subst Abuse Treat; 2004 Oct; 27(3):187-93. PubMed ID: 15501371
[TBL] [Abstract][Full Text] [Related]
20. Using the DATCAP and ASI to estimate the costs and benefits of residential addiction treatment in the State of Washington.
French MT; Salomé HJ; Carney M
Soc Sci Med; 2002 Dec; 55(12):2267-82. PubMed ID: 12409139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
